Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Up – Here’s What Happened

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) gapped up prior to trading on Tuesday . The stock had previously closed at $16.78, but opened at $17.26. Daiichi Sankyo shares last traded at $16.9550, with a volume of 9,411 shares traded.

Wall Street Analyst Weigh In

DSNKY has been the subject of several research reports. Jefferies Financial Group lowered shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. Zacks Research cut shares of Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a report on Monday, August 3rd. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Reduce”.

Daiichi Sankyo Price Performance

The company has a current ratio of 2.42, a quick ratio of 1.64 and a debt-to-equity ratio of 0.18. The stock has a 50 day simple moving average of $16.77 and a 200-day simple moving average of $17.38. The firm has a market cap of $32.77 billion, a PE ratio of 20.45, a price-to-earnings-growth ratio of 3.04 and a beta of -0.18.

Daiichi Sankyo (OTCMKTS:DSNKY) last announced its quarterly earnings data on Friday, July 31st. The company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.01). Daiichi Sankyo had a net margin of 10.92% and a return on equity of 14.22%. The business had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.32 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. Equities analysts anticipate that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.93 earnings per share for the current fiscal year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.